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Abstract
A common feature of pathological fibrosis involving the lung and other organs is the persistent activation of
myofibroblasts in injured tissues. Recent evidence supports the role of a member of the NADPH oxidase (NOX)
gene family, NOX4, in myofibroblast differentiation, matrix synthesis and contractility. Additionally, NOX4 may
contribute directly or indirectly to alveolar epithelial cell death, while myofibroblasts themselves acquire an
apoptosis-resistant phenotype. Thus, NOX4 may be responsible for the cardinal features of progressive fibrosis -
myofibroblast activation and epithelial cell dysrepair. Therapeutic targeting of NOX4 is likely to be effective in
progressive cases of fibrosis involving multiple organs.
Introduction
Fibrosis of mammalian tissues/organs is perhaps best
understood as an evolutionarily conserved, adaptive tissue
response to injury. In most pathological scenarios when
tissue fibrosis is observed, there appears to be an asso-
ciated impairment in regeneration of the adjacent airway/
luminal epithelium or vascular endothelium. Natural selec-
tion appears to have favored the development of fibrosis at
sites of wounding or injury, at the expense of complete
restoration of tissue architecture and function. It makes
teleological sense that the more immediate need for survi-
val of the organism from bleeding and infection would
take precedence over a temporary (often reversible), and
often marginal, loss of organ functions. Indeed in multiple
plant and animal species, formations of extracellular
matrix (ECM) “scars” around traumatic, non-infectious
and/or infectious injury are “normal” responses that serve
to limit the invasion/spread of the pathogen at the site of
injury/infection [1]. An illustrative example of this tissue
response in humans is in the formation of a fibrotic scar
around Mycobacterium tuberculosis bacilli, without which
an estimated third of world’s population infected with this
infectious agent would not be expected to survive for very
long [2]. Thus, fibrosis may be considered as part of innate
host defense mechanisms against infection, or the per-
ceived threat of infection (non-infectious injury). The
enigma in many human highly lethal fibrotic disorders, in
particular idiopathic pulmonary fibrosis (IPF), is the cur-
rent, lack of understanding of: (1) the etiology of the
apparent injury/infection, and (2) the progressive nature of
the fibrotic process. Here, I address these issues with a
greater focus on the second problem related to fibrosis
progression and a potential role for NOX4 in this process.
Etiological considerations in IPF
Pulmonary fibrosis results from a large number of known
causes (e.g. organic and inorganic dust exposures); how-
ever, a specific etiological agent in IPF has not been identi-
fied [3]. A number of risk factors have been identified;
these include inhalational exposures, including cigarette
smoking, gastroesophageal reflux, diabetes mellitus, and
advanced age. Given the natural course of the disease and
the epidemiologcal data supporting the concept that IPF is
an age-associated disease [4], one possibility is that this
results from a failure of “maintenance regeneration” due
to a combination of chronic, subclinical insults in a subset
of genetically-susceptible, elderly patients (Figure 1).
Indeed, telomerase mutations have been identified in
familial IPF [5,6], and shortened telomeres appear to be a
risk factor for sporadic IPF [7]. Fibrosis associated with
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“injury-provoked regeneration” which may be easier to
recognize clinically due to the relative acuteness of disease
onset and progression, as in diseases such as hypersensitiv-
ity pneumonitis.
Fibrosis progression: persistence of tissue
myofibroblasts
While a number of acute/subacute lung injuries that
result in fibrosis are at least partially reversible, IPF is
not. A key feature of these clinical syndromes in diverse
organ systems is the persistence of tissue myofibroblasts
in actively remodeling tissues. The local activation of tis-
sue myofibroblasts are a highly conserved and stereotypic
response to injury [8], and is fundamental to a broader
biological principle in development, maintenance, and
injury-repair responses of mammalian tissues/organs -
perpetual and dynamic epithelial-mesenchymal-endothe-
lial interactions.
In the repair response to injury, activation of local myo-
fibroblast precursors occurs early and their disappearance
is a hallmark of fibrosis resolution [9]. Mechanisms that
lead to myofibroblast apoptosis in physiologic wound-
repair, however, remain unclear; it has been postulated
that cross-linking of a contracted ECM shields myofibro-
blasts from biomechanical stress and that loss of mechani-
cal tension may induce myofibroblast apoptosis [8,10,11].
Similarly, the mechanisms of an apparent “apoptosis-resis-
tant” myofibroblast phenotype in progressive fibrotic dis-
orders, including IPF, are not well defined [12]. The
presence, activation, and survival of myofibroblasts in
fibrotic tissues explains several morphological, physiologi-
cal, and clinical features, including the “fibrocontractive”
nature of histopathological changes characterized by
alveolar collapse, reduced lung compliance, restrictive phy-
siology, and progression.
Our studies have demonstrated that, in addition to myo-
fibroblast differentiation, the pro-fibrotic cytokine, trans-
forming growth factor-b1 (TGF-b1), promotes
myofibroblast differentiation [13]. TGF-b1 activates two
pro-survival signaling pathways, focal adhesion kinase
(FAK) and protein kinase B (PKB/AKT) by mechanisms
that involve cell adhesion and release of soluble growth
factors, respectively [13,14]; both pathways contribute
combinatorially to myofibroblast survival [15]. Impor-
tantly, the administration of a protein kinase inhibitor that
modulates the activities of these pro-survival pathways
attenuates fibrosis in a model of bleomycin-induced lung
fibrosis [16]. Further studies of the potential role of these
pathways as a common mechanism of apoptosis resistance
of myofibroblasts in IPF or in individualized patients
requires further study.
More recent studies from our laboratory support the
role of a member of the NADPH oxidase (NOX) family,
NOX4, in myofibroblast differentiation/survival. NOX4
was identified as one of the most highly upregulated
genes in transcriptomal (Affymetrix) analyses of human
lung fibroblasts treated with TGF-b1 [17]. NOX4 activa-
tion mediates generation of hydrogen peroxide (H2O2),
myofibroblast differentiation, contractility, and ECM pro-
duction in response to TGF-b1, effects that also seen in
human IPF-derived (myo)fibroblasts [17]. In human tis-
sues of IPF patients, the expression of NOX4 is localized
to myofibroblasts, both within fibroblastic foci and in
remodeled blood vessels, as well as in epithelial cells
associated aberrant bronchiolization [17]. Therapeutic
targeting of this NOX isoform protects against fibrosis in
two different animal models of injury-provoked pulmon-
ary fibrosis [17]. Work by other investigators suggest that
NOX4 may play a pro-fibrotic role by inducing apoptosis
of lung epithelial cells [18]. Epithelial cell death may also
be mediated indirectly by the paracrine secretion of
H2O2 by activated myofibroblasts [19]. These observa-
tions, in addition to the purported role of NOX4 in vas-
cular remodeling [20,21], suggest that NOX4 mediates
effects on multiple cell types and tissue compartments
that contribute to organ fibrosis.
Figure 1 Hypothetical model of a central role of NADPH
oxidase-4 (NOX4) in pathological fibrosis: Aging, environmental
and genetic/epigenetic factors influence the persistent expression/
activation of NADPH oxidase 4 (NOX4) in fibrotic tissues. This may
be due to aberrations in injury repair responses or in maintenance
regeneration, resulting in a failure to maintain cellular homeostasis
in fibrotic tissues. Loss of tissue homeostasis is characterized by
myofibroblast activation and epithelial cell dysrepair, with their
attendant cellular phenotypes, that promotes pathological tissue
fibrosis.
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Conclusion
Progressive fibrotic disorders are associated with an apop-
tosis-resistant myofibroblast phenotype. The mechanisms
that give rise to this myofibroblast phenotype may include
the acquisition of pro-survival signaling pathways and
expression/activation of NOX4. Paradoxically, activation
of NOX4 and generation of extracellular H2O2 may pro-
mote the death of adjacent epithelial cells [19], setting up
a feed-forward mechanism for fibrosis linked to impair-
ments in epithelial regenerative capacity that would lead
to progressive fibrosis. Targeting molecules and signaling
pathways that promote survival of myofibroblasts repre-
sents a promising therapeutic strategy in clinical syn-
dromes characterized by progressive of fibrosis, including
IPF.
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